Welcome to our dedicated page for HEMAB THERAPEUTICS HOLDINGS news (Ticker: COAG), a resource for investors and traders seeking the latest updates and insights on HEMAB THERAPEUTICS HOLDINGS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect HEMAB THERAPEUTICS HOLDINGS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of HEMAB THERAPEUTICS HOLDINGS's position in the market.
Hemab Therapeutics (Nasdaq: COAG) closed its upsized initial public offering on May 4, 2026, selling 19,262,500 shares at $18.00 per share, including 2,512,500 shares from full exercise of the underwriters' option. Gross proceeds were approximately $346.7 million.
The company’s common stock began trading on the Nasdaq Global Select Market on May 1, 2026 under ticker COAG. A registration statement was declared effective April 30, 2026.
Hemab Therapeutics (Nasdaq: COAG) priced an upsized initial public offering of 16,750,000 shares at $18.00 per share, with a 30-day underwriter option for an additional 2,512,500 shares.
Gross proceeds are expected to be approximately $301.5 million before underwriting discounts, and trading on the Nasdaq Global Select Market is expected to begin on May 1, 2026 with closing on or about May 4, 2026.